CA2642260C - Intravenous antiviral treatments - Google Patents

Intravenous antiviral treatments Download PDF

Info

Publication number
CA2642260C
CA2642260C CA2642260A CA2642260A CA2642260C CA 2642260 C CA2642260 C CA 2642260C CA 2642260 A CA2642260 A CA 2642260A CA 2642260 A CA2642260 A CA 2642260A CA 2642260 C CA2642260 C CA 2642260C
Authority
CA
Canada
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2642260A
Other languages
English (en)
French (fr)
Other versions
CA2642260A1 (en
Inventor
Yarlagadda Sudhakara Babu
Pooran Chand
Shanta Bantia
Shane Arnold
John Michael Kilpatrick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocryst Pharmaceuticals Inc
Original Assignee
Biocryst Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38169715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2642260(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2006/013535 external-priority patent/WO2007117241A1/en
Application filed by Biocryst Pharmaceuticals Inc filed Critical Biocryst Pharmaceuticals Inc
Publication of CA2642260A1 publication Critical patent/CA2642260A1/en
Application granted granted Critical
Publication of CA2642260C publication Critical patent/CA2642260C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2642260A 2006-02-13 2007-02-12 Intravenous antiviral treatments Active CA2642260C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77274806P 2006-02-13 2006-02-13
US60/772,748 2006-02-13
USPCT/US2006/013535 2006-04-12
PCT/US2006/013535 WO2007117241A1 (en) 2006-04-12 2006-04-12 Intramuscular antiviral treatments
PCT/US2007/003755 WO2007095218A1 (en) 2006-02-13 2007-02-12 Intravenous antiviral treatments

Publications (2)

Publication Number Publication Date
CA2642260A1 CA2642260A1 (en) 2007-08-23
CA2642260C true CA2642260C (en) 2016-08-09

Family

ID=38169715

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2642260A Active CA2642260C (en) 2006-02-13 2007-02-12 Intravenous antiviral treatments

Country Status (11)

Country Link
EP (1) EP1986626A1 (https=)
JP (3) JP2009538822A (https=)
KR (9) KR102267754B1 (https=)
AU (2) AU2007215156A1 (https=)
BR (1) BRPI0707769A2 (https=)
CA (1) CA2642260C (https=)
EA (1) EA025483B1 (https=)
HK (1) HK1212250A1 (https=)
MX (2) MX2008010394A (https=)
MY (1) MY166063A (https=)
WO (1) WO2007095218A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102267754B1 (ko) * 2006-02-13 2021-06-23 바이오크리스트 파마수티컬즈, 인코퍼레이티드 정맥내 항바이러스 치료
CN101367750B (zh) * 2007-08-14 2012-05-23 中国人民解放军军事医学科学院毒物药物研究所 (1s,2s,3s,4r)-3-[(1s)-1-乙酰氨-2-乙基-丁基]-4-胍基-2-羟基-环戊基-1-羧酸水合物及其医药用途
KR20220033561A (ko) 2020-09-07 2022-03-17 주식회사 경보제약 페라미비르 화합물을 포함하는 프리믹스 제형의 제약학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO121027B1 (ro) * 1996-06-14 2006-11-30 Biocryst Pharmaceuticals, Inc. Compuşi ciclopentanici substituiţi, compoziţiifarmaceutice şi utilizarea acestora
CA2315262C (en) * 1997-12-17 2009-11-10 Biocryst Pharmaceuticals, Inc. Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
GB0015324D0 (en) * 2000-06-22 2000-08-16 Biota Scient Management Medicaments
KR102267754B1 (ko) * 2006-02-13 2021-06-23 바이오크리스트 파마수티컬즈, 인코퍼레이티드 정맥내 항바이러스 치료

Also Published As

Publication number Publication date
KR20230003248A (ko) 2023-01-05
KR102475176B1 (ko) 2022-12-07
JP2009538822A (ja) 2009-11-12
CA2642260A1 (en) 2007-08-23
JP2015180695A (ja) 2015-10-15
MX2008010394A (es) 2009-01-12
BRPI0707769A2 (pt) 2011-05-10
KR101992585B9 (ko) 2022-09-20
MX2020002008A (es) 2020-07-13
KR20190072681A (ko) 2019-06-25
KR20180024027A (ko) 2018-03-07
KR20160129105A (ko) 2016-11-08
AU2013216632A1 (en) 2013-08-29
AU2013216632B2 (en) 2016-09-01
JP6073202B2 (ja) 2017-02-01
KR20080096829A (ko) 2008-11-03
KR20140132778A (ko) 2014-11-18
KR20200143519A (ko) 2020-12-23
KR20210076189A (ko) 2021-06-23
MX393640B (es) 2025-03-21
WO2007095218A1 (en) 2007-08-23
KR20210135632A (ko) 2021-11-15
EA025483B1 (ru) 2016-12-30
KR101992585B1 (ko) 2019-06-25
EP1986626A1 (en) 2008-11-05
KR102267754B1 (ko) 2021-06-23
KR102194015B1 (ko) 2020-12-22
AU2007215156A1 (en) 2007-08-23
MY166063A (en) 2018-05-23
KR102323339B1 (ko) 2021-11-08
EA200870263A1 (ru) 2009-06-30
HK1212250A1 (en) 2016-06-10
JP2013256527A (ja) 2013-12-26

Similar Documents

Publication Publication Date Title
US12121503B2 (en) Antiviral treatments
CA2642260C (en) Intravenous antiviral treatments
CN104784166A (zh) 抗病毒化合物、包含该化合物的剂型及其用途
AU2016262644B2 (en) Intravenous antiviral treatments
JP2009538822A5 (https=)
NZ570538A (en) Intravenous antiviral treatments
US20110015264A1 (en) Intramuscular antiviral treatments

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241216

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241216

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241216

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260203